Growth, infection, and humoral immunity in children who are HIV exposed and uninfected

This study reveals that HIV-exposed uninfected (HEU) infants exhibit transient, sex-specific differences in growth, infection rates, and immune profiles compared to unexposed peers, highlighting the importance of considering sex as a key parameter in assessing their health.

The Gist

Imagine a group of newborn babies as two different teams of runners starting a race. One team is the HUU (HIV-Unexposed Uninfected), born to mothers who never had HIV. The other team is the HEU (HIV-Exposed Uninfected), born to mothers who did have HIV but were treated with medication so the babies didn't catch the virus.

For a long time, doctors knew that the HEU runners often stumbled more often and got tired faster than the HUU runners. But nobody was sure why, or if it was the same for boys and girls. This study is like a detailed stopwatch and camera crew following these two teams for their first year of life to see how they grow, how often they get sick, and how their immune systems (their internal "security guards") are working.

Here is what they found, broken down simply:

1. The Growth Race: Boys vs. Girls

Think of growth like a plant growing in a garden.

• The Boys: The HEU boys had a bit of a rough start. At 3 months, they were slightly shorter and lighter than the HUU boys. By the time they hit 12 months, they were still a bit shorter in height compared to their HUU peers. It's as if the HEU boys had a slightly smaller "growth engine" that took a little longer to catch up.
• The Girls: The HEU girls had a different hiccup. At 6 months, they were more likely to be "stunted" (not growing tall enough) compared to HUU girls. However, by the end of the year, these differences started to fade.

The Takeaway: Being exposed to HIV in the womb (even if you don't get infected) seems to act like a temporary "speed bump" for growth, but it hits boys and girls in slightly different ways and at different times.

2. The Cold and Flu Season: Who Gets Sick?

Imagine the babies are walking through a busy marketplace full of germs (viruses).

• The Common Colds: The most common invaders were Rhinovirus (the common cold) and CMV (a very common virus that usually hides quietly). Almost every baby, regardless of their team, got these.
• The Gender Gap: At 9 months, the HEU boys were twice as likely to have a runny nose (rhinorrhea) as the HUU boys. It's like the HEU boys' "nose shields" were a little weaker at that specific age.
• The Twist: By 12 months, the tables turned. The HEU girls actually had fewer fevers and coughs than the HUU girls. It seems the HEU girls might have developed a slightly stronger immune defense against these bugs by the end of the year.

The Takeaway: The HEU babies aren't necessarily getting more infections overall, but the timing and type of sickness can differ based on whether they are a boy or a girl.

3. The Security Guards: Antibodies

Every baby is born with a "starter pack" of security guards (antibodies) borrowed from their mother. These guards protect the baby until their own security team is trained.

• The Handoff: The study checked how well these borrowed guards were passed down. Surprisingly, the HEU mothers passed down their antibodies just as well as the HUU mothers.
• The Retention: The HEU girls actually kept their borrowed CMV guards a little longer than the HUU girls. The HEU boys, however, started with slightly fewer guards against a specific virus (Enterovirus) at birth.
• The Result: By the time the babies were 9 months old, almost all the borrowed guards had left the building for everyone. The babies then had to rely on their own newly trained security teams.

The Takeaway: The "starter pack" of protection wasn't broken. The differences in sickness weren't because the HEU babies got a bad handoff of antibodies, but perhaps because their own immune systems matured at slightly different speeds.

The Big Picture

Think of this study as realizing that sex matters.

For a long time, scientists looked at HEU babies as one big group. This study says, "Wait a minute! We need to look at the boys and girls separately."

• The Verdict: HEU babies are doing pretty well overall, especially with modern medicine. They aren't falling behind drastically.
• The Catch: They do face some temporary, sex-specific challenges. The boys might struggle a bit more with height and runny noses early on, while the girls might have a different immune rhythm.

Why does this matter?
It's like knowing that a specific type of car needs a different tune-up depending on whether it's a sedan or a truck. By understanding these sex differences, doctors can give better, more personalized care to ensure every HEU baby gets the boost they need to run their race successfully. The study concludes that while the "HIV exposure" is a factor, the baby's sex is a key variable we can't ignore when checking their health.

Technical Summary

1. Problem Statement

Children who are HIV-exposed but uninfected (HEU) exhibit higher morbidity and mortality rates compared to their HIV-unexposed uninfected (HUU) peers, despite not being infected with HIV themselves. While Prevention of Mother-to-Child Transmission (PMTCT) programs have successfully reduced perinatal HIV transmission, the underlying mechanisms driving the increased susceptibility to infections and growth deficits in HEU infants remain poorly understood.

Existing literature often focuses on single aspects (e.g., specific infections or isolated immune markers) and frequently fails to account for sex differences, which are increasingly recognized as critical biological variables in immune development. This study addresses the gap in understanding the interplay between maternal HIV exposure, infant sex, growth trajectories, infection burden, and humoral immunity during the first year of life.

2. Methodology

• Study Design: A prospective longitudinal cohort study conducted in Yaoundé, Cameroon, from June 2022 to May 2024.
• Participants:
  • Cohort: 107 pregnant women living with HIV (on cART) and 103 pregnant women without HIV.
  • Infants: 196 live births (103 HEU, 94 HUU) were followed from birth to 12 months.
  • Retention: 193 children completed at least one follow-up visit (63.8% retention rate).
• Data Collection & Visits:
  • Visits occurred at birth, 14 weeks (3 months), 6, 9, and 12 months.
  • Anthropometry: Weight, length/height, head circumference, and mid-upper arm circumference were measured to calculate Z-scores (WAZ, HAZ, WHZ, BAZ, HCZ) based on WHO standards.
  • Clinical Symptoms: Maternally reported symptoms included fever, cough, diarrhea, rhinorrhea, skin rash, and vomiting.
  • Sample Collection: Venous blood (cord, maternal, infant), buccal, nasal, and rectal swabs were collected.
• Laboratory Assays:
  • Pathogen Detection: Quantitative real-time PCR (qPCR) and RT-qPCR were used to screen for Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV), Rhinovirus, Influenza A & B, Rotavirus, and Malaria. Viral loads were normalized (e.g., CMV to Albumin).
  • Humoral Immunity: Total IgG antibody titers against CMV, RSV, and Enterovirus were measured via ELISA.
• Statistical Analysis:
  • Mixed-effects regression models were used to assess growth trajectories, adjusting for socioeconomic status (SES), maternal age, and gestational age.
  • Sex-stratified analyses were performed for all outcomes.
  • Significance was set at $P < 0.05$.

3. Key Contributions

• Sex-Stratified Analysis: The study explicitly separates data by sex, revealing that HEU infants do not constitute a monolithic group; males and females exhibit distinct vulnerabilities in growth and infection.
• Integrated Approach: It simultaneously evaluates growth, clinical symptoms, PCR-confirmed pathogen burden, and antibody dynamics, providing a holistic view of HEU health.
• Longitudinal Depth: Tracking infants from birth to 12 months allows for the observation of transient vs. persistent differences in immune and growth development.

4. Key Results

A. Growth Outcomes

• Male HEU Infants: Showed significantly lower Height-for-Age Z-scores (HAZ) compared to male HUU peers ($\beta$ -0.75; $P=0.047$) in adjusted mixed-effect models. They also had transiently lower Weight-for-Age Z-scores (WAZ) at 3 months.
• Female HEU Infants: Exhibited transiently higher rates of stunting at 6 months (21% vs. 0% in HUU; $P=0.01$).
• Overall: Growth deficits were sex-specific and largely transient, with males showing persistent linear growth deficits (HAZ) through 12 months.

B. Infection Burden & Symptoms

• Dominant Pathogens: CMV and Rhinovirus were the most prevalent infections (33.9%–61.7% and 25.3%–50.0% respectively). Rotavirus, Malaria, RSV, and Influenza were rare (<5.5%).
• Symptom Prevalence:
  • Rhinorrhea: Male HEU infants had a significantly higher risk of rhinorrhea at 9 months (RR=2.29; $P=0.02$) compared to male HUU.
  • Fever/Cough: Female HEU infants showed a lower prevalence of fever and cough at 12 months compared to female HUU.
• Viremia: Female HEU infants had lower CMV viremia at 9 months compared to female HUU.

C. Humoral Immunity (Antibody Dynamics)

• CMV: Antibody levels peaked at birth and declined over time. Female HEU infants had significantly higher CMV antibody titers at 3 months compared to female HUU ($P=0.04$), suggesting efficient maternal transfer or retention.
• RSV & Enterovirus: Antibody levels followed expected decay curves. Male HEU infants had significantly lower Enterovirus titers at birth ($P=0.0066$).
• Conclusion on Immunity: Overall, antibody decay and acquisition patterns were similar between HEU and HUU groups, suggesting that HIV exposure does not fundamentally impair the ability to acquire or lose maternal antibodies, though sex-specific transient differences exist.

5. Significance and Conclusion

• Transient Vulnerability: The study concludes that while HEU infants generally have comparable health outcomes to HUU peers, they experience transient, sex-specific vulnerabilities. Male HEU infants are more prone to linear growth deficits and respiratory symptoms (rhinorrhea) early in life, while female HEU infants show different stunting patterns and immune retention profiles.
• Sex as a Biological Variable: The findings underscore the necessity of stratifying pediatric HIV research by sex. Ignoring sex differences may obscure specific health risks faced by HEU males (growth) vs. females (stunting patterns).
• Clinical Implications: The data suggests that while PMTCT is effective, HEU infants require close monitoring for growth faltering (particularly in males) and respiratory infections during the first year. The study supports the hypothesis that early disparities are often compensated for by immune maturation over time.
• Limitations: The authors note potential bias in self-reported symptoms and the need for cellular immune phenotyping to fully understand the mechanisms behind the observed sex differences.

In summary, this paper provides robust evidence that maternal HIV exposure interacts with infant sex to create temporary but significant disparities in growth and infection susceptibility, highlighting the need for sex-specific monitoring in HEU care protocols.